Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Medical Oncology, 2012
Abramson Cancer Center
Perelman Center for Advanced Medicine, West Pavilion, 3rd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.
Esserman L, Yeee D, DeMichele A, Yau C, Issacs C, Symmans WF, Albain K, Chen Yunn-yi, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocoo A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Yang S, Adams A, Chein AJ, Forero-Torres T, Stringer-Reasor E, Wallace AM, Pusztai L, Boughry JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Visvcusi RK, Euhus DM, Edison KK, Chi AY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Layland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, van 't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paolini M, Clennel JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Beery DA: Disease-free survival correlates with pathologic complete response in the adaptively randomized I-SPY2 trial of stage 2/3 breast cancer The Lancet : 2020.
McDonald E, Doot RK, Carlin SD, Pantel A, Shah PD, Clark AS, Desai H, Kelly G, Young AJ, Pryma DA, Farewell MD, Nayak A, Lee H, Schubert EK, Makvandi M, Xiober A, Tchou J, DeMichele A, Feldman M, Domchek SM, Mach RH, Maxwell KN, Manoff: PARP Imaging in Breast Bancer JAMA Oncology : 2020.
Clark AS,: Refining the indications for neoadjuvant chemotherapy (NAC) for patients with HER2+ breast cancer – a single institution experience Journal of Surgical Oncology : 2020.
Nivar I, Kaufmann T, Bayne L, Goodspeed B, Chodosh L, Feldman M, Wileyto P, Clark AS, DeMichele A: Patient attitudes, experience and results of screening for minimal residual disease (MRD) for therapeutic intervention San Antonio Texas Breast Cancer Symposium® : 2019.
Nivar I, Kaufmann T, Bayne L, Goodspeed B, Chodosh L, Feldman M, Wileyto P, Clark A, DeMichele A: Patient attitudes, experience and results of screening for minimal residual disease (MRD) for therapeutic intervention San Antonio Texas Breast Cancer Symposium® : 2019.
Yau C, DeMichele A, Symmans W, Pusztai L, Yee D, CLark AS, Hatzis C, Matthews JB, Carter J, Chen Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, Sahoo S, Albian KS, Chien A, Edminston KK, Elias AD, Ellis ED, Euhus DM, Han HS, Issacs C, Kahn OJ, Lang JE, Lu J, Meisel JL, Mitri Z, Nanda R, Northfelt DW, Sanft T, Stringer-Reasor E, Viscusi RK, Wallace AM, Yung R, Hylton NM, Boughey JC, Melisko ME, Perlmutter J, Rugo HS, Schwab R, Van't Veer LJ, Berry DA, Esserman LJ: Site of recurrence after neoadjuvant therapy: clues to biology and impact on endpoints San Antonio Texas Breast Cancer Symposium® : 2019.
Bardia, A., Hurvitz, S., DeMichele, A., Clark, A.S., Zelnak, A., Yardley, D., Karuturi, M., Sanft, T., Blau, S., Hart, L., Mia, C., Caria, N., Purkayastha, D., Mistry, A., Moulder, S.: Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): efficacy, safety, and biomarker results ASCO 2019 – TRINITI-1, Chicago Illinois : 2019.
Dreyfuss AD, Barsky AR, Taunk NK, Clark AS, Freedman GM: The Efficacy and Safety of Hypofractionated Radiotherapy with Concurrent Anti-HER-2 Therapy Following Breast-Conserving Therapy for Breast Cancer The Breast Journal : 2019.
Mankoff DA, Clark AS: PET oestrogen receptor imaging: ready for the clinic? The Lancet Oncology : 2019.
Elmi, A., Makvandi, M., Weng, C.C., Hou, C., Clark, AS., Mach, R.H., Mankoff, D.A.: Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT. Clin Cancer Res : 2019.
Division of Hematology Oncology Perelman Center for Advanced Medicine10th Floor, South PavilionOffice #10-1543400 Civic Center Boulevard
Phone: (215) 662-7096
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.